Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma
Affiliations: Department of Urology, The University of Tokyo Hospital, Tokyo 113‑8655, Japan, Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113‑8655, Japan, Department of Urology, Keio University School of Medicine, Tokyo 160‑8582, Japan, Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo 113‑0033, Japan
- Published online on: June 16, 2022 https://doi.org/10.3892/ol.2022.13384
- Article Number: 265
Copyright: © Teshima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.